Paclitaxel Accord 6 mg/ml concentraat voor oplossing voor infusie
As listed in the register: Paclitaxel Accord 6 mg/ml concentraat voor oplossing voor infusie
6 mg/ml · concentraat voor oplossing voor infusie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Paclitaxel
- Made by
- Accord Healthcare B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (PACLITAXEL). It describes the substance, not this exact product.
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization.
This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
Less than 1% of the total administered dose was excreted in urine as the metabolites 6α-hydroxypaclitaxel and 3′- p -hydroxypaclitaxel.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-15
Safety of the active substance
From the US prescribing label for the same active substance (PACLITAXEL). It describes the substance, not this exact product.
WARNING: SEVERE MYELOSUPPRESSION.
- Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is contraindicated in patients with:.
- Baseline neutrophil counts of < 1,500 cells/mm 3 [see Warnings and Precautions (5.1) ].
- A history of severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Warnings and Precautions (5.5) ].
- Neutrophil counts of < 1,500 cells/mm 3.
The most common adverse reactions (≥ 20%) with single-agent use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea [see Adverse Reactions (6.1) ].
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Accord Healthcare B.V. |
|---|---|
| Active substance | Paclitaxel |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 6 mg/ml |
| Form | concentraat voor oplossing voor infusie |
| Classification | L01CD01 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | 102965 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.